280 related articles for article (PubMed ID: 34991418)
1. Factor IX(a) inhibitors: an updated patent review (2003-present).
Afosah DK; Ofori E; Mottamal M; Al-Horani RA
Expert Opin Ther Pat; 2022 Apr; 32(4):381-400. PubMed ID: 34991418
[TBL] [Abstract][Full Text] [Related]
2. Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present).
Al-Horani RA
Expert Opin Ther Pat; 2020 Jan; 30(1):39-55. PubMed ID: 31847619
[No Abstract] [Full Text] [Related]
3. Factor XIa inhibitors: A review of the patent literature.
Al-Horani RA; Desai UR
Expert Opin Ther Pat; 2016; 26(3):323-45. PubMed ID: 26881476
[TBL] [Abstract][Full Text] [Related]
4. Anticoagulation beyond direct thrombin and factor Xa inhibitors: indications for targeting the intrinsic pathway?
van Montfoort ML; Meijers JC
Thromb Haemost; 2013 Aug; 110(2):223-32. PubMed ID: 23739841
[TBL] [Abstract][Full Text] [Related]
5. Factors IX, XI, and XII: potential therapeutic targets for anticoagulant therapy in atherothrombosis.
Rai V; Balters MW; Agrawal DK
Rev Cardiovasc Med; 2019 Dec; 20(4):245-253. PubMed ID: 31912715
[TBL] [Abstract][Full Text] [Related]
6. Factor XI inhibition fulfilling the optimal expectations for ideal anticoagulation.
Székely O; Borgi M; Lip GYH
Expert Opin Emerg Drugs; 2019 Mar; 24(1):55-61. PubMed ID: 30845846
[TBL] [Abstract][Full Text] [Related]
7. Discovery methods of coagulation-inhibiting drugs.
Gómez-Outes A; García-Fuentes M; Suárez-Gea ML
Expert Opin Drug Discov; 2017 Dec; 12(12):1195-1205. PubMed ID: 28952381
[TBL] [Abstract][Full Text] [Related]
8. Factor XII(a) inhibitors: a review of the patent literature.
Kalinin DV
Expert Opin Ther Pat; 2021 Dec; 31(12):1155-1176. PubMed ID: 34142629
[No Abstract] [Full Text] [Related]
9. Investigational anticoagulants for hematological conditions: a new generation of therapies.
Denas G; Pengo V
Expert Opin Investig Drugs; 2013 Oct; 22(10):1281-94. PubMed ID: 23876036
[TBL] [Abstract][Full Text] [Related]
10. Management of Severe Bleeding in Patients Treated With Oral Anticoagulants: Proceedings Monograph From the Emergency Medicine Cardiac Research and Education Group-International Multidisciplinary Severe Bleeding Consensus Panel October 20, 2018.
Gibler WB; Racadio JM; Hirsch AL; Roat TW
Crit Pathw Cardiol; 2019 Sep; 18(3):143-166. PubMed ID: 31348075
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic Agents.
Chan NC; Weitz JI
Circ Res; 2019 Feb; 124(3):426-436. PubMed ID: 30702990
[TBL] [Abstract][Full Text] [Related]
12. Factor XI and factor XII as targets for new anticoagulants.
Weitz JI
Thromb Res; 2016 May; 141 Suppl 2():S40-5. PubMed ID: 27207423
[TBL] [Abstract][Full Text] [Related]
13. Factor XI inhibitors: cardiovascular perspectives.
De Caterina R; Prisco D; Eikelboom JW
Eur Heart J; 2023 Jan; 44(4):280-292. PubMed ID: 36263776
[TBL] [Abstract][Full Text] [Related]
14. The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review.
Pinto DJ; Qiao JX; Knabb RM
Expert Opin Ther Pat; 2012 Jun; 22(6):645-61. PubMed ID: 22655676
[TBL] [Abstract][Full Text] [Related]
15. New anticoagulants: how to deal with treatment failure and bleeding complications.
Kazmi RS; Lwaleed BA
Br J Clin Pharmacol; 2011 Oct; 72(4):593-603. PubMed ID: 21752066
[TBL] [Abstract][Full Text] [Related]
16. Targeting factor XI(a) for anticoagulation therapy: a patent landscape.
Al-Horani RA
Pharm Pat Anal; 2020 Jan; 9(1):3-5. PubMed ID: 32057285
[No Abstract] [Full Text] [Related]
17. The potential of aptamers as anticoagulants.
Nimjee SM; Rusconi CP; Harrington RA; Sullenger BA
Trends Cardiovasc Med; 2005 Jan; 15(1):41-5. PubMed ID: 15795162
[TBL] [Abstract][Full Text] [Related]
18. Contemporary medicinal-chemistry strategies for discovery of blood coagulation factor Xa inhibitors.
Hao X; Zuo X; Kang D; Zhang J; Song Y; Liu X; Zhan P
Expert Opin Drug Discov; 2019 Sep; 14(9):915-931. PubMed ID: 31172842
[No Abstract] [Full Text] [Related]
19. A Review of FXIa Inhibition as a Novel Target for Anticoagulation.
Koulas I; Spyropoulos AC
Hamostaseologie; 2023 Feb; 43(1):28-36. PubMed ID: 36807817
[TBL] [Abstract][Full Text] [Related]
20. Novel fondaparinux protocol for anticoagulation therapy in adults with renal failure and suspected heparin-induced thrombocytopenia: a retrospective review of institutional protocol.
Ghaziri D; Dehaini H; Msheik M; Bahmad M; Zorkot M; Saad GA
BMC Pharmacol Toxicol; 2023 Jan; 24(1):2. PubMed ID: 36639796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
